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Empowerment and protection
Sept 16 marks the second Global Female Condom Day, 
when the US National Female Condom Coalition and the 
Universal Access to Female Condoms Joint Programme 
encourage advocacy and education around these little-
used products that can “empower and protect”. Why 
do female condoms need their own global day and are 
things set to change?
Female condoms are listed by the UN Commission on 
Life-Saving Commodities for Women and Children as 
one of the “essential but underutilised” commodities 
necessary to accelerate improvements in reproductive, 
maternal, child, and newborn health. The Commission 
describes the female condom as “the only barrier 
contraception that gives women and adolescent girls 
greater control over protecting themselves from HIV, 
other STIs and unintended pregnancy”. Yet several 
obstacles prevent the product from reaching the level 
of use enjoyed by the male condom. First, the average 
procurement cost is a relatively expensive US$0·57 
compared with $0·03 for male condoms, and the cost 
of service provision is also more expensive because 
providers need training in demonstrating how to use 
the product. Second, few studies have been done to test 
the eﬀ ectiveness of the female condom at preventing 
sexually transmitted infections (STIs). Third, awareness 
is low from the perspective of the user and of national 
governments. Fourth, there is little variety in the design 
of a product which can be diﬃ  cult to use at ﬁ rst.
This ﬁ nal obstacle is addressed in an Article in this 
month’s issue by Mags Beksinska and colleagues. When 
the study began, only one design of female condom, 
catchily named the FC2, was licensed by both WHO 
and the US Food and Drug Administration (FDA) and 
was approved for bulk procurement by UN agencies. 
Since FDA licensing and UN Population Fund (UNFPA) 
prequaliﬁ cation require studies to demonstrate the 
functional performance of new designs, Beksinska 
and colleagues did a randomised, non-inferiority 
trial in China and South Africa to compare the 
performance of three new designs of female condom 
against the FC2 device. The functional performance 
(deﬁ ned as the frequency of user-reported breakage 
or misplacement) of the three new products, which all 
diﬀ er fairly signiﬁ cantly in terms of shape, materials, 
and lubrication, was no worse than for the FC2 condom. 
As a result, one of the new products, the Cupid female 
condom (manufactured in India), secured UNFPA 
prequaliﬁ cation in July last year.
Will the public-sector procurement of new designs 
of female condom improve uptake? Maria Gallo and 
colleagues discuss this likelihood in their Comment. 
They suggest that having a wider choice of contraceptive 
products that diﬀ er enough in terms of cost, duration 
of eﬀ ect, and side-eﬀ ects can drive up demand. Yet 
more needs to be done, they suggest. Hard data on the 
eﬀ ectiveness of female condoms at preventing STIs 
might better convince policy makers to support the 
products, and implementation research is needed to 
explore what drives enthusiasm for female condoms 
among their small band of devoted users worldwide.
In other research in this issue, Rhoda Wanyenze and 
colleagues report the results of another randomised trial 
of the eﬀ ects of abbreviated HIV counselling and testing 
on sexual risk behaviour in Uganda. An abbreviated 
strategy of provider-initiated HIV counselling and testing 
(ie, that oﬀ ered to patients who attend health centres 
for any diagnosis) has been adopted in Uganda since 
2006. The strategy, which frees up precious health-
worker time, largely skips personalised risk-assessment 
and pretest counselling, yet the eﬀ ects of eliminating 
these elements have not been tested. Wanyenze and 
colleagues show that the abbreviated strategy is non-
inferior to traditional counselling and testing protocols 
in terms of reported levels of unprotected sex in the 
year after testing. The study also assessed an enhanced 
linkage to care intervention for those found HIV-positive. 
The enhanced care package decreased time to the start 
of treatment in men and entry into HIV care in women, 
suggesting that resources might be better directed at 
care linkage and retention of those found HIV-positive 
than at extensive counselling before testing.
Finally, we join The Lancet in announcing its annual 
Highlights photography competition. Both journals 
seek arresting health-related images from daily life and 
practice in any part of the world. Winning entries will be 
published in The Lancet and could also feature as a cover 
image in The Lancet Global Health.
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